WANBURY
Back to Income Statement
|
WANBURY Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹600 Cr | ₹578 Cr | ₹500 Cr | ₹511 Cr | ₹393 Cr |
What is the latest Revenue of WANBURY ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹600 Cr |
| Mar2024 | ₹578 Cr |
| Mar2023 | ₹500 Cr |
| Mar2022 | ₹511 Cr |
| Mar2021 | ₹393 Cr |
How is Revenue of WANBURY Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹600 Cr | 3.77 | |
| Mar2024 | ₹578 Cr | 15.63 | |
| Mar2023 | ₹500 Cr | -2.26 | |
| Mar2022 | ₹511 Cr | 30.23 | |
| Mar2021 | ₹393 Cr | - | |
Compare Revenue of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹901.5 Cr | -6% | 2.9% | 6.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹429,469.0 Cr | -2.5% | 1% | 7.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹173,305.0 Cr | -3.1% | 0.3% | -1.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹146,014.0 Cr | -4.9% | 2.8% | 37.8% | Stock Analytics | |
| CIPLA | ₹111,388.0 Cr | -1.6% | 5.6% | -5.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,381.0 Cr | -3.2% | -3.1% | 4.8% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | -6% |
2.9% |
6.2% |
| SENSEX | -2.4% |
-3.7% |
-9.2% |
You may also like the below Video Courses